People who survived a bleeding stroke appeared to get similar protection from a low-dose, three-drug blood pressure pill whether or not their kidneys were working well, according to a new analysis presented Nov. 9 at the American Heart Association's Scientific Sessions in Chicago. The pill's developer, George Medicines, announced the findings.
The analysis is post hoc, meaning researchers looked at the data in a way the trial was not designed to test. It cannot prove the pill works equally well in every kidney group, and some of the subgroup results were not statistically significant on their own.